CDDO-imidazolide Targets Multiple Amino Acid Residues on the Nrf2 Adaptor, Keap1
- 10 September 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (17), 9965-9976
- https://doi.org/10.1021/acs.jmedchem.0c01088
Abstract
Synthetic triterpenoids including CDDO, its methyl ester (CDDO-Me, bardoxolone methyl), and its imidazolide (CDDO-Im) enhance Nrf2-mediated antioxidant and anti-inflammatory activity in many diseases by reacting with thiols on the adaptor protein, Keap1. Unlike monofunctional CDDO-Me, the bifunctional analog, CDDO-Im, has a second reactive site (imidazolide) and can covalently bind to amino acids other than cysteine on target proteins such as glutathione Stransferase pi (GSTP), serum albumin, or Keap1. Here we show for the first time that bifunctional CDDO-Im (in contrast to CDDO-Me), as low as 50 nM, can covalently transacylate arginine and serine residues in GSTP and cross-link them to adjacent cysteine residues. Moreover, we show that CDDO-Im binds covalently to Keap1 by forming permanent Michael adducts with eight different cysteines, and acyl adducts with lysine and several tyrosine residues. Modeling studies suggest that the Tyr 85 adduct stabilizes the Keap1-Cul3 complex, thereby enhancing the potency of CDDO-Im.Funding Information
- Medical Research Council (MR/L006758/1)
- Triterpenoid Therapeutics, Inc.
This publication has 46 references indexed in Scilit:
- The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox HomeostasisPhysiological Reviews, 2018
- Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes StudyAmerican Journal of Nephrology, 2018
- Complete Protection against Aflatoxin B1-Induced Liver Cancer with a Triterpenoid: DNA Adduct Dosimetry, Molecular Signature, and Genotoxicity ThresholdCancer Prevention Research, 2014
- The Keap1-Nrf2 System Prevents Onset of Diabetes MellitusMolecular and Cellular Biology, 2013
- Synthetic Oleanane Triterpenoids: Multifunctional Drugs with a Broad Range of Applications for Prevention and Treatment of Chronic DiseasePharmacological Reviews, 2012
- Proteomic Analysis Shows Synthetic Oleanane Triterpenoid Binds to mTORPLOS ONE, 2011
- New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative StressJournal of Natural Products, 2011
- Platforms and networks in triterpenoid pharmacologyDrug Development Research, 2007
- Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signalingThe EMBO Journal, 2006
- Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stressProceedings of the National Academy of Sciences of the United States of America, 2005